Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Bio-Rad is a multinational life science and clinical diagnostics company operating in two segments: Life Science (40% of sales) and Clinical Diagnostics (60% of sales). The company develops, manufactures, and markets instruments, systems, reagents, and consumables for research and clinical laboratories globally. Approximately 60% of net sales are derived from international locations, with Europe being the largest region.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Net Sales | $2,583.2 | $2,566.5 |
| Gross Profit | $1,339.9 | $1,378.9 |
| Gross Margin | 51.9% | 53.7% |
| Operating Income | $47.2 | $269.0 |
| Net Income (Loss) | $759.9 | $(1,844.2) |
| Diluted EPS | $27.85 | $(65.36) |
| Operating Cash Flow | $532.2 | $455.2 |
| Total Debt (Long-term) | $1,201.7 | $1,200.4 |
| Cash & Short-term Investments | $1,540.7 | $1,664.5 |
Note: Net Income for 2025 includes a significant non-operating gain of $900.4 million from changes in the fair market value of equity securities (primarily Sartorius AG). Operating income excludes this item.
Material Changes vs. Prior Period
- Revenue: Net sales increased 0.7% to $2.58 billion. On a currency-neutral basis, sales were essentially flat. Life Science sales decreased 0.7% (driven by constrained academic/biotech funding), while Clinical Diagnostics sales increased 1.6% (driven by quality control and blood typing products).
- Margins: Consolidated gross margin decreased 1.8 percentage points to 51.9%. This was driven by one-time inventory write-offs in Life Science and higher material costs/reduced fixed manufacturing absorption in both segments.
- Impairments: The company recorded $172.8 million in impairment charges for purchased intangibles. This includes a $127.7 million charge for the discontinued development of Curiosity Diagnostics (Clinical Diagnostics) and an $81.7 million charge for Dropworks (Life Science).
- Non-Operating Volatility: The company reported a $900.4 million gain from changes in the fair market value of equity securities and loan receivables, primarily due to an $872.6 million holding gain on its investment in Sartorius AG. This contrasts with a $2.66 billion loss in the same category in 2024.
- Acquisitions: Acquired Stilla Technologies in June 2025 for approximately $257.7 million in net assets, adding to the Life Science segment.
Guidance, Outlook, and Risks
- Outlook: Management expects challenging global economic and geopolitical conditions to continue in 2026. Reduced government spending and challenges in the biopharma market are expected to negatively impact the business. The market in China remains uncertain.
- Capital Allocation: The company repurchased $295.5 million of Class A common stock in 2025. As of year-end, $284.6 million remained available under the share repurchase program.
- Key Risks:
- Sartorius Investment: Changes in the market value of the Sartorius AG position materially impact financial results and could cause the company to be deemed an investment company under the Investment Company Act of 1940.
- Geopolitics & Trade: Exposure to international operations (60% of sales) creates risks related to tariffs, trade barriers, and geopolitical instability (e.g., Russia-Ukraine, Middle East conflicts).
- Regulatory: Subject to FDA and EU IVDR regulations; potential changes in reimbursement rates for clinical diagnostics could reduce demand.
- Supply Chain: Reliance on sole suppliers for certain components and potential disruptions from tariffs or logistics issues.
Investor Verification Checklist
- Sartorius Valuation: Verify the fair value of the $5.67 billion investment in Sartorius AG and the sensitivity of net income to fluctuations in its share price.
- Intangible Asset Impairments: Review the rationale and future prospects for the Dropworks and Curiosity Diagnostics technologies following the $172.8 million write-down.
- Operating Cash Flow Quality: Confirm that the $532.2 million operating cash flow is sustainable without the non-cash gains from equity securities.
- Debt Covenants: Assess compliance with the maximum consolidated leverage ratio covenant under the $200 million revolving credit facility.
- China Exposure: Evaluate the specific impact of moderating economic growth and government policy changes in China on the mid-single digit percentage of sales derived from that region.